Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
State-of-the-Art Molecular Oncology in Taiwan
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

State-of-the-Art Molecular Oncology in Taiwan

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 6754

Special Issue Editors

Dr. Yuh-Min Chen

E-Mail Website
Guest Editor
1. School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
2. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
Interests: chemotherapy; epidermal growth factor receptor (EGFR); immunotherapy; lung cancer; molecular oncology; precision medicine; targeted therapy
Dr. Jacqueline Whang-Peng

E-Mail Website
Guest Editor
1. Consultant and Visiting Staff, Taipei Municipal Wanfang Hospital, Taipei 116081, Taiwan
2. Member, TMU Research Center of Cancer Translational Medicine, Taipei 110301, Taiwan
Interests: hemato-oncology; oncogenetics
Prof. Dr. Chih-Jen Yang

E-Mail Website
Guest Editor
1. Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2. Chair, School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Chair, Lung Cancer Team, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Interests: lung cancer; target therapy; immunotherapy; antiangiogenic agent; chemotherapy; NGS
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We have witnessed tremendous advances in our understanding of the pathogenesis of cancer in the past three decades, leading to development of new chemotherapy, targeted therapy, and immunotherapy. It is clear that cancer arises through a multistep, mutagenic process whereby cancer cells acquire a common set of properties, including unlimited proliferation, self-sufficiency in growth signals, tissue invasion and metastases, sustained angiogenesis, evading and resistance to apoptosis, and evading immune surveillance, through but not limited to many common cancer signal transduction pathway, such as cell cycle, Hippo, Myc, PI3K/Akt, RTK-RAS, EGFR, VEGF, p53, Notch, TGF-b, and b-catenin/Wnt pathway. Of course, there are also some specific dysregulated pathways for specific type of cancers. Translational and clinical studies have shown that the majority of cancer patients could receive specific precision targeted therapy, immunotherapy, or chemotherapy, according to these findings.

In this Special Issue, we try to update current status of molecular and translational oncology studies of different types of solid or hematological cancers in Taiwan, and provide an opportunity to cooperate between Taiwan experts and international professionals.

Dr. Yuh-Min Chen
Dr. Jacqueline Whang-Peng
Prof. Dr. Chih-Jen Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • lung cancer
  • breast cancer
  • head and neck cancer
  • colon cancer
  • immunotherapy
  • targeted therapy
  • chemotherapy
  • EGFR
  • VEGF
  • TGF-β
  • PI3K/Akt
  • RTK-RAS

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1620 KiB  
Article
A Genome-Wide Association Study Identified Novel Genetic Susceptibility Loci for Oral Cancer in Taiwan
by Da-Tian Bau, Ting-Yuan Liu, Chia-Wen Tsai, Wen-Shin Chang, Jian Gu, Jai-Sing Yang, Liang-Chun Shih and Fuu-Jen Tsai
Int. J. Mol. Sci. 2023, 24(3), 2789; https://doi.org/10.3390/ijms24032789 - 1 Feb 2023
Cited by 6 | Viewed by 2346
Abstract
Taiwan has the highest incidence rate of oral cancer in the world. Although oral cancer is mostly an environmentally induced cancer, genetic factors also play an important role in its etiology. Genome-wide association studies (GWAS) have identified nine susceptibility regions for oral cancers [...] Read more.
Taiwan has the highest incidence rate of oral cancer in the world. Although oral cancer is mostly an environmentally induced cancer, genetic factors also play an important role in its etiology. Genome-wide association studies (GWAS) have identified nine susceptibility regions for oral cancers in populations of European descent. In this study, we performed the first GWAS of oral cancer in Taiwan with 1529 cases and 44,572 controls. We confirmed two previously reported loci on the 6p21.33 (HLA-B) and 6p21.32 (HLA-DQ gene cluster) loci, highlighting the importance of the human leukocyte antigen and, hence, the immunologic mechanisms in oral carcinogenesis. The TERT-CLMPT1L locus on 5p15.33, the 4q23 ADH1B locus, and the LAMC3 locus on 9q34.12 were also consistent in the Taiwanese. We found two new independent loci on 6p21.32, rs401775 in SKIV2L gene and rs9267798 in TNXB gene. We also found two suggestive novel Taiwanese-specific loci near the TPRS1 gene on 8q23.3 and in the TMED3 gene on 15q25.1. This study identified both common and unique oral cancer susceptibility loci in the Taiwanese as compared to populations of European descent and shed significant light on the etiology of oral cancer in Taiwan. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Taiwan)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

15 pages, 521 KiB  
Review
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
by Yung-Hung Luo, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou and Yuh-Min Chen
Int. J. Mol. Sci. 2022, 23(13), 7037; https://doi.org/10.3390/ijms23137037 - 24 Jun 2022
Cited by 5 | Viewed by 3726
Abstract
Lung cancers are life-threatening malignancies that cause great healthcare burdens in Taiwan and worldwide. The 5-year survival rate for Taiwanese patients with lung cancer is approximately 29%, an unsatisfactorily low number that remains to be improved. We first reviewed the molecular epidemiology derived [...] Read more.
Lung cancers are life-threatening malignancies that cause great healthcare burdens in Taiwan and worldwide. The 5-year survival rate for Taiwanese patients with lung cancer is approximately 29%, an unsatisfactorily low number that remains to be improved. We first reviewed the molecular epidemiology derived from a deep proteogenomic resource in Taiwan. The nuclear factor erythroid 2-related factor 2 (NRF2)antioxidant mechanism was discovered to mediate the oncogenesis and tumor progression of lung adenocarcinoma. Additionally, DNA replication, glycolysis and stress response are positively associated with tumor stages, while cell-to-cell communication, signaling, integrin, G protein coupled receptors, ion channels and adaptive immunity are negatively associated with tumor stages. Three patient subgroups were discovered based on the clustering analysis of protein abundance in tumors. The first subgroup is associated with more advanced cancer stages and visceral pleural invasion, as well as higher mutation burdens. The second subgroup is associated with EGFR L858R mutations. The third subgroup is associated with PI3K/AKT pathways and cell cycles. Both EGFR and PI3K/AKT signaling pathways have been shown to induce NRF2 activation and tumor cell proliferation. We also reviewed the clinical evidence of patient outcomes in Taiwan given various approved targeted therapies, such as EGFR-tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK)inhibitors, in accordance with the patients’ characteristics. Somatic mutations occurred in EGFR, KRAS, HER2 and BRAF genes, and these mutations have been detected in 55.7%, 5.2%, 2.0% and 0.7% patients, respectively. The EGFR mutation is the most prevalent targetable mutation in Taiwan. EML4-ALK translocations have been found in 9.8% of patients with wild-type EGFR. The molecular profiling of advanced NSCLC is critical to optimal therapeutic decision-making. The patient characteristics, such as mutation profiles, protein expression profiles, drug-resistance profiles, molecular oncogenic mechanisms and patient subgroup systems together offer new strategies for personalized treatments and patient care. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Taiwan)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop